Drugs / ESG406
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06979674 | Jun 2025 → Apr 2028 expected | — | Shanghai Escugen Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESG406 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06979674 ↗ |
| Route | Intravenous | “Administered via intravenous (IV) infusion.” NCT06979674 ↗ |